ArticleMedicine2026
Circulating tumor plasma cells correlate with tumor burden and routine laboratory markers in newly diagnosed multiple myeloma: A retrospective single-center study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor plasma cells (CTPCs) detected by multiparameter flow cytometry may serve as a minimally invasive marker of disease burden in multiple myeloma (MM). However, the relationship between CTPC burden, routine laboratory parameters, and bone marrow (BM) involvement remains insufficiently characterized in regional clinical settings. This retrospective single-center study included 51 consecutive patients with newly diagnosed MM. Peripheral blood CTPCs were quantified using ten-color flow cytometry. Among them, 41 patients with evaluable CTPC data were stratified into CTPC-higher (n = 20) and CTPC-lower (n = 21) groups using a 0.07% cutoff. Laboratory variables and immunophenotypic features were compared between groups, and correlations were assessed using Spearman rank analysis. Exploratory logistic regression adjusted for age and sex was performed, and Benjamini-Hochberg false-discovery-rate correction was applied to multiple comparisons. Compared with the CTPC-lower group, the CTPC-higher group had lower hemoglobin levels (73.5 vs 107.0 g/L; P < .001), lower albumin levels (30.9 vs 38.2 g/L; P = .006), higher β2-microglobulin levels (6.97 vs 3.25 mg/L; P = .004), and higher BM plasma cell percentages on smear examination (34.75% vs 12.00%; P = .005). CTPC levels were positively correlated with BM plasma cell percentage on smear examination (ρ = 0.67; P < .001) and negatively correlated with hemoglobin levels (ρ=-0.68; P < .001). These group differences and correlations remained significant after false-discovery-rate correction (all q ≤ 0.018). In age- and sex-adjusted analyses, hemoglobin, albumin, β2-microglobulin, and BM plasma cell percentage on smear remained associated with CTPC-higher status. Higher peripheral blood CTPC levels were associated with greater BM tumor burden and more abnormal routine laboratory markers in patients with newly diagnosed MM. CTPC quantification may serve as an adjunctive marker for baseline disease assessment in regional clinical settings. These cross-sectional findings from this limited sample do not establish prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.